Inhibiting proliferation and metastasis of osteosarcoma cells by downregulation of long non‑coding RNA colon cancer‑associated transcript 2 targeting microRNA‑143 Retraction in /10.3892/ol.2023.13665

Bi,Fengjiang; Chen,Can; Fu,Jing; Yu,Lei; Geng,Jia

doi:10.3892/ol.2021.12526

Inhibiting proliferation and metastasis of osteosarcoma cells by downregulation of long non‑coding RNA colon cancer‑associated transcript 2 targeting microRNA‑143

Retraction in: /10.3892/ol.2023.13665

Authors:
- Fengjiang Bi
- Can Chen
- Jing Fu
- Lei Yu
- Jia Geng
View Affiliations

Affiliations: Department of Orthopedics, The First Hospital of Qiqihaer, Qiqihaer, Heilongjiang 161005, P.R. China
Published online on: February 8, 2021 https://doi.org/10.3892/ol.2021.12526
Article Number: 265
Copyright: © Bi et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Osteosarcoma is a malignant bone tumor, which has a high incidence in children and adolescents. However, the pathogenesis of osteosarcoma remains unclear. Long noncoding RNA (lncRNA) is a new potential therapeutic target and diagnostic biomarker for osteosarcoma. Hence, the present study aimed to explore the effect of lncRNA colon cancer‑associated transcript (CCAT2) on osteosarcoma and its potential underlying mechanisms. For this purpose, the proliferation of osteosarcoma cells was measured using the CCK‑8 assay. The scratch‑wound and cell invasion assays were used to determine the migration and invasion of osteosarcoma cells, respectively. LncRNA CCAT2 and microRNA (miR)‑143 binding sites were identified by the dual‑luciferase reporter assay. RNA and protein expression levels were detected by reverse‑transcription quantitative PCR and western blotting, respectively. Downregulation of lncRNA CCAT2 inhibited the proliferation, migration, and invasion of osteosarcoma cells. The findings also revealed that miR‑143 bound directly to lncRNA CCAT2. The expression of miR‑143 was upregulated by the knockdown of lncRNA CCAT2. Downregulation of the FOS‑like antigen 2 was also observed after knockdown of lncRNA CCAT2. The function of lncRNA CCAT2 in osteosarcoma cells was attenuated by co‑transfection with anti‑miR‑143 oligodeoxyribonucleotide. In conclusion, downregulation of lncRNA CCAT2 inhibited the proliferation and metastasis of osteosarcoma cells by targeting miR‑143. lncRNA CCAT2 was identified as a potential target for osteosarcoma treatment.

View Figures

View References

1	Siegel RL, Miller KD and Jemal A: Cancer statistics, 2020. CA Cancer J Clin. 70:7–30. 2020. View Article : Google Scholar : PubMed/NCBI
2	Ratti M, Lampis A, Ghidini M, Salati M, Mirchev MB, Valeri N and Hahne JC: MicroRNAs (miRNAs) and long non-coding RNAs (lncRNAs) as new tools for cancer therapy: first steps from bench to bedside. Target Oncol. 15:261–278. 2020. View Article : Google Scholar : PubMed/NCBI
3	Gutschner T, Richtig G, Haemmerle M and Pichler M: From biomarkers to therapeutic targets-the promises and perils of long non-coding RNAs in cancer. Cancer Metastasis Rev. 37:83–105. 2018. View Article : Google Scholar : PubMed/NCBI
4	Shi X, Zhang W, Nian X, Lu X, Li Y, Liu F, Wang F, He B, Zhao L, Zhu Y, et al: The previously uncharacterized lncRNA APP promotes prostate cancer progression by acting as a competing endogenous RNA. Int J Cancer. 146:475–486. 2020. View Article : Google Scholar : PubMed/NCBI
5	Wang H, Huo X, Yang XR, He J, Cheng L, Wang N, Deng X, Jin H, Wang N, Wang C, et al: STAT3-mediated upregulation of lncRNA HOXD-AS1 as a ceRNA facilitates liver cancer metastasis by regulating SOX4. Mol Cancer. 16:1362017. View Article : Google Scholar : PubMed/NCBI
6	Pan J, Fang S, Tian H, Zhou C, Zhao X, Tian H, He J, Shen W, Meng X, Jin X, et al: lncRNA JPX/miR-33a-5p/Twist1 axis regulates tumorigenesis and metastasis of lung cancer by activating Wnt/β-catenin signaling. Mol Cancer. 19:92020. View Article : Google Scholar : PubMed/NCBI
7	Ba Z, Gu L, Hao S, Wang X, Cheng Z and Nie G: Downregulation of lncRNA CASC2 facilitates osteosarcoma growth and invasion through miR-181a. Cell Prolif. 51:e124092018. View Article : Google Scholar
8	Shen B, Zhou N, Hu T, Zhao W, Wu D and Wang S: LncRNA MEG3 negatively modified osteosarcoma development through regulation of miR-361-5p and FoxM1. J Cell Physiol. 234:13464–13480. 2019. View Article : Google Scholar : PubMed/NCBI
9	Zhao Z, Wang J, Wang S, Chang H, Zhang T and Qu J: LncRNA CCAT2 promotes tumorigenesis by over-expressed Pokemon in non-small cell lung cancer. Biomed Pharmacother. 87:692–697. 2017. View Article : Google Scholar : PubMed/NCBI
10	Chen X, Liu L and Zhu W: Up-regulation of long non-coding RNA CCAT2 correlates with tumor metastasis and poor prognosis in cervical squamous cell cancer patients. Int J Clin Exp Pathol. 8:13261–13266. 2015.PubMed/NCBI
11	Zhang J, Jiang Y, Zhu J, Wu T, Ma J, Du C, Chen S, Li T, Han J and Wang X: Overexpression of long non-coding RNA colon cancer-associated transcript 2 is associated with advanced tumor progression and poor prognosis in patients with colorectal cancer. Oncol Lett. 14:6907–6914. 2017.PubMed/NCBI
12	Ruan R and Zhao XL: LncRNA CCAT2 enhances cell proliferation via GSK3β/β-catenin signaling pathway in human osteosarcoma. Eur Rev Med Pharmacol Sci. 22:2978–2984. 2018.PubMed/NCBI
13	Yan L, Wu X, Yin X, Du F, Liu Y and Ding X: LncRNA CCAT2 promoted osteosarcoma cell proliferation and invasion. J Cell Mol Med. 22:2592–2599. 2018. View Article : Google Scholar : PubMed/NCBI
14	Zhang C, Ma K and Li WY: Cinobufagin suppresses the characteristics of osteosarcoma cancer cells by inhibiting the IL-6-OPN-STAT3 pathway. Drug Des Devel Ther. 13:4075–4090. 2019. View Article : Google Scholar : PubMed/NCBI
15	Qu H, Xue Y, Lian W, Wang C, He J, Fu Q, Zhong L, Lin N, Lai L, Ye Z, et al: Melatonin inhibits osteosarcoma stem cells by suppressing SOX9-mediated signaling. Life Sci. 207:253–264. 2018. View Article : Google Scholar : PubMed/NCBI
16	Eggers B, Marciniak J, Memmert S, Kramer FJ, Deschner J and Nokhbehsaim M: The beneficial effect of cold atmospheric plasma on parameters of molecules and cell function involved in wound healing in human osteoblast-like cells in vitro. Odontology. 108:607–616. 2020. View Article : Google Scholar : PubMed/NCBI
17	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
18	Chu Q, Jiang Y, Zhang W, Xu C, Du W, Tuguzbaeva G, Qin Y, Li A, Zhang L, Sun G, et al: Pyroptosis is involved in the pathogenesis of human hepatocellular carcinoma. Oncotarget. 7:84658–84665. 2016. View Article : Google Scholar : PubMed/NCBI
19	Sun X, Dai G, Yu L, Hu Q, Chen J and Guo W: miR-143-3p inhibits the proliferation, migration and invasion in osteosarcoma by targeting FOSL2. Sci Rep. 8:6062018. View Article : Google Scholar : PubMed/NCBI
20	Endicott AA, Morimoto LM, Kline CN, Wiemels JL, Metayer C and Walsh KM: Perinatal factors associated with clinical presentation of osteosarcoma in children and adolescents. Pediatr Blood Cancer. 64:642017. View Article : Google Scholar : PubMed/NCBI
21	Strauss SJ and Whelan JS: Current questions in bone sarcomas. Curr Opin Oncol. 30:252–259. 2018. View Article : Google Scholar : PubMed/NCBI
22	Rasmussen TP: Parallels between artificial reprogramming and the biogenesis of cancer stem cells: Involvement of lncRNAs. Semin Cancer Biol. 57:36–44. 2019. View Article : Google Scholar : PubMed/NCBI
23	Rynkeviciene R, Simiene J, Strainiene E, Stankevicius V, Usinskiene J, Miseikyte Kaubriene E, Meskinyte I, Cicenas J and Suziedelis K: Non-coding RNAs in glioma. Cancers (Basel). 11:172018. View Article : Google Scholar
24	Jiang Y, Du W, Chu Q, Qin Y, Tuguzbaeva G, Wang H, Li A, Li G, Li Y, Chai L, et al: Downregulation of long non-coding RNA Kcnq1ot1: an important mechanism of arsenic trioxide-induced long QT syndrome. Cell Physiol Biochem. 45:192–202. 2018. View Article : Google Scholar : PubMed/NCBI
25	Ma N, Tie C, Yu B, Zhang W and Wan J: Identifying lncRNA-miRNA-mRNA networks to investigate Alzheimer's disease pathogenesis and therapy strategy. Aging (Albany NY). 12:2897–2920. 2020. View Article : Google Scholar : PubMed/NCBI
26	Huang X, Ta N, Zhang Y, Gao Y, Hu R, Deng L, Zhang B, Jiang H and Zheng J: Microarray analysis of the expression profile of long non-coding RNAs indicates lncRNA RP11-263F15.1 as a biomarker for diagnosis and prognostic prediction of pancreatic ductal adenocarcinoma. J Cancer. 8:2740–2755. 2017. View Article : Google Scholar : PubMed/NCBI
27	Wang H, Wu J, Zhang X, Ding L and Zeng Q: Microarray analysis of the expression profile of lncRNAs reveals the key role of lncRNA BC088327 as an agonist to heregulin 1β induced cell proliferation in peripheral nerve injury. Int J Mol Med. 41:3477–3484. 2018.PubMed/NCBI
28	Li J, Zhu Y, Wang H and Ji X: Targeting long noncoding rna in glioma: a pathway perspective. Mol Ther Nucleic Acids. 13:431–441. 2018. View Article : Google Scholar : PubMed/NCBI
29	Chen W, Hang Y, Xu W, Wu J, Chen L, Chen J, Mao Y, Song J, Song J and Wang H: BLACAT1 predicts poor prognosis and serves as oncogenic lncRNA in small-cell lung cancer. J Cell Biochem. 2018.
30	Dai W, Mu L, Cui Y, Li Y, Chen P, Xie H and Wang X: Berberine promotes apoptosis of colorectal cancer via regulation of the long non-coding RNA (lncRNA) cancer susceptibility candidate 2 (CASC2)/AU-binding factor 1 (AUF1)/B-cell CLL/lymphoma 2 (Bcl-2) axis. Med Sci Monit. 25:730–738. 2019. View Article : Google Scholar : PubMed/NCBI
31	Ling H, Spizzo R, Atlasi Y, Nicoloso M, Shimizu M, Redis RS, Nishida N, Gafà R, Song J, Guo Z, et al: CCAT2, a novel noncoding RNA mapping to 8q24, underlies metastatic progression and chromosomal instability in colon cancer. Genome Res. 23:1446–1461. 2013. View Article : Google Scholar : PubMed/NCBI
32	Chen S, Wu H, Lv N, Wang H, Wang Y, Tang Q, Shao H and Sun C: LncRNA CCAT2 predicts poor prognosis and regulates growth and metastasis in small cell lung cancer. Biomed Pharmacother. 82:583–588. 2016. View Article : Google Scholar : PubMed/NCBI
33	Wu SW, Hao YP, Qiu JH, Zhang DB, Yu CG and Li WH: High expression of long non-coding RNA CCAT2 indicates poor prognosis of gastric cancer and promotes cell proliferation and invasion. Minerva Med. 108:317–323. 2017.PubMed/NCBI
34	Wang CY, Hua L, Yao KH, Chen JT, Zhang JJ and Hu JH: Long non-coding RNA CCAT2 is up-regulated in gastric cancer and associated with poor prognosis. Int J Clin Exp Pathol. 8:779–785. 2015.PubMed/NCBI
35	Zhou N, Si Z, Li T, Chen G, Zhang Z and Qi H: Long non-coding RNA CCAT2 functions as an oncogene in hepatocellular carcinoma, regulating cellular proliferation, migration and apoptosis. Oncol Lett. 12:132–138. 2016. View Article : Google Scholar : PubMed/NCBI
36	Xu Y, Wang B, Zhang F, Wang A, Du X, Hu P, Zhu Y and Fang Z: Long non-coding RNA CCAT2 is associated with poor prognosis in hepatocellular carcinoma and promotes tumor metastasis by regulating Snail2-mediated epithelial-mesenchymal transition. OncoTargets Ther. 10:1191–1198. 2017. View Article : Google Scholar
37	Chen F, Bai G, Li Y, Feng Y and Wang L: A positive feedback loop of long noncoding RNA CCAT2 and FOXM1 promotes hepatocellular carcinoma growth. Am J Cancer Res. 7:1423–1434. 2017.PubMed/NCBI
38	Yu Y, Nangia-Makker P, Farhana L and Majumdar APN: A novel mechanism of lncRNA and miRNA interaction: CCAT2 regulates miR-145 expression by suppressing its maturation process in colon cancer cells. Mol Cancer. 16:1552017. View Article : Google Scholar : PubMed/NCBI
39	Zhu H, Dougherty U, Robinson V, Mustafi R, Pekow J, Kupfer S, Li YC, Hart J, Goss K, Fichera A, et al: EGFR signals downregulate tumor suppressors miR-143 and miR-145 in Western diet-promoted murine colon cancer: Role of G1 regulators. Mol Cancer Res. 9:960–975. 2011. View Article : Google Scholar : PubMed/NCBI
40	Yan X, Chen X, Liang H, Deng T, Chen W, Zhang S, Liu M, Gao X, Liu Y, Zhao C, et al: miR-143 and miR-145 synergistically regulate ERBB3 to suppress cell proliferation and invasion in breast cancer. Mol Cancer. 13:2202014. View Article : Google Scholar : PubMed/NCBI
41	Hu Y, Ou Y, Wu K, Chen Y and Sun W: miR-143 inhibits the metastasis of pancreatic cancer and an associated signaling pathway. Tumour Biol. 33:1863–1870. 2012. View Article : Google Scholar : PubMed/NCBI
42	Dong X, Lv B, Li Y, Cheng Q, Su C and Yin G: miR-143 regulates the proliferation and migration of osteosarcoma cells through targeting MAPK7. Arch Biochem Biophys. 630:47–53. 2017. View Article : Google Scholar : PubMed/NCBI
43	Wang Q, Cai J, Wang J, Xiong C and Zhao J: miR-143 inhibits EGFR-signaling-dependent osteosarcoma invasion. Tumour Biol. 35:12743–12748. 2014. View Article : Google Scholar : PubMed/NCBI
44	Liu H, Wang H, Liu H and Chen Y: Effect of miR-143 on the apoptosis of osteosarcoma cells. Int J Clin Exp Pathol. 8:14241–14246. 2015.PubMed/NCBI